|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2002-8-22
|
|
pubmed:abstractText |
Forty-five patients with high-risk myeloid malignancies (32 acute myeloid leukemia and 13 high-risk myelodysplastic syndromes) were treated with fludarabine, cytarabine, idarubicin, and G-CSF (FLAG-IDA). Twenty-four (53%) patients achieved complete remission (CR), and five (11%) partial remission. Infection predominantly with pulmonary involvement was the most common regimen-related toxicity. Mucositis (15 patients) and pulmonary toxicity (19 patients) were the most frequently observed non-hematologic side effects. There were four early deaths and 12 patients presented with resistant disease. Overall survival (OS) at 12 months was 40%. The FLAG-IDA regimen shows evident antileukemic activity in patients with high-risk myeloid malignancies with acceptable toxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0145-2126
|
|
pubmed:author |
pubmed-author:AndreuRafaelR,
pubmed-author:BenllochLuisL,
pubmed-author:CerveraJoséJ,
pubmed-author:GarcíaInmaculadaI,
pubmed-author:JarqueIsidroI,
pubmed-author:JiménezCarmenC,
pubmed-author:MartínGuillermoG,
pubmed-author:MartínezJesúsJ,
pubmed-author:MolláSusanaS,
pubmed-author:MoscardóFedericoF,
pubmed-author:RegaderaAnaA,
pubmed-author:SanzGuillermoG,
pubmed-author:SanzMiguelM,
pubmed-author:de la RubiaJavierJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
725-30
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12191567-Acute Disease,
pubmed-meshheading:12191567-Adolescent,
pubmed-meshheading:12191567-Adult,
pubmed-meshheading:12191567-Aged,
pubmed-meshheading:12191567-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12191567-Cytarabine,
pubmed-meshheading:12191567-Female,
pubmed-meshheading:12191567-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:12191567-Humans,
pubmed-meshheading:12191567-Idarubicin,
pubmed-meshheading:12191567-Infection,
pubmed-meshheading:12191567-Leukemia, Myeloid,
pubmed-meshheading:12191567-Male,
pubmed-meshheading:12191567-Middle Aged,
pubmed-meshheading:12191567-Myelodysplastic Syndromes,
pubmed-meshheading:12191567-Recombinant Proteins,
pubmed-meshheading:12191567-Remission Induction,
pubmed-meshheading:12191567-Risk Factors,
pubmed-meshheading:12191567-Survival Analysis,
pubmed-meshheading:12191567-Treatment Outcome,
pubmed-meshheading:12191567-Vidarabine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.
|
|
pubmed:affiliation |
Hematology Service, University Hospital La Fe, Valencia, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
